Literature DB >> 6124756

Treatment of dialysis osteomalacia with desferrioxamine.

D J Brown, J K Dawborn, K N Ham, J M Xipell.   

Abstract

Two patients with severe dialysis osteomalacia, whose fractures and deformities had become progressively worse over 3 years, were treated with desferrioxamine (DFO). They improved rapidly and over 6 months were able to stop taking analgesics and return to normal activities. Pre-treatment bone biopsy samples contained extensive osteoid covering trabecular surfaces. Electron microscopy showed morphological abnormalities in the matrix. Treatment brought about a decrease in the extent and depth of osteoid, but matrix abnormalities remained. Energy-dispersive X-ray microanalysis showed the presence of several metals not seen in normal bone. The changes in trace metals after DFO treatment were not consistent. Atomic absorption analysis showed no significant change in the aluminium content of bone with treatment. DFO appears to be an effective treatment for severe dialysis osteomalacia.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6124756     DOI: 10.1016/s0140-6736(82)90544-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  11 in total

Review 1.  The role of chelation in the treatment of other metal poisonings.

Authors:  Silas W Smith
Journal:  J Med Toxicol       Date:  2013-12

2.  [Mid C regional parathyroid hormone in the clinical workup: diagnostic value in extrarenal (primary) and renal (secondary) hyperparathyroidism].

Authors:  H Jüppner; M Atkinson; B Ringe; H P Krohn; R D Hesch
Journal:  Klin Wochenschr       Date:  1986-03-17

3.  Case report 294. Diagnosis: dialysis osteomalacia with response to desferrioxamine therapy.

Authors:  J M Xipell; K N Ham; D J Brown; J K Dawborn
Journal:  Skeletal Radiol       Date:  1984       Impact factor: 2.199

Review 4.  Oxygen toxicity, oxygen radicals, transition metals and disease.

Authors:  B Halliwell; J M Gutteridge
Journal:  Biochem J       Date:  1984-04-01       Impact factor: 3.857

5.  Total parathyroidectomy and parathyroid autograft for renal osteodystrophy: analysis of the cause of failure.

Authors:  P Kinnaert; J L Vanherweghem; M Fuss; A Schoutens; P Bergmann; M Dratwa; J van Geertruyden
Journal:  World J Surg       Date:  1985-06       Impact factor: 3.352

6.  Effects of aluminum(III), chromium(III), and iron(III) on the rate of dissolution of calcium hydroxyapatite crystals in the absence and presence of the chelating agent desferrioxamine.

Authors:  M R Christoffersen; H C Thyregod; J Christoffersen
Journal:  Calcif Tissue Int       Date:  1987-07       Impact factor: 4.333

7.  Aluminum transfer as glutamate complex through blood-brain barrier. Possible implication in dialysis encephalopathy.

Authors:  R Deloncle; O Guillard; F Clanet; P Courtois; A Piriou
Journal:  Biol Trace Elem Res       Date:  1990-04       Impact factor: 3.738

8.  Differential diagnosis between secondary hyperparathyroidism and aluminum intoxication in uremic patients: usefulness of 99mTc-pyrophosphate bone scintigraphy.

Authors:  P Kinnaert; I Van Hooff; A Schoutens; P Bergmann; M Fuss; M Dratwa; A Vienne; J L Pasteels; J van Geertruyden; J L Vanherweghem
Journal:  World J Surg       Date:  1989 Mar-Apr       Impact factor: 3.352

9.  Aluminum deposition at the osteoid-bone interface. An epiphenomenon of the osteomalacic state in vitamin D-deficient dogs.

Authors:  L D Quarles; V W Dennis; H J Gitelman; J M Harrelson; M K Drezner
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

10.  Inhibition of autoimmune neuropathological process by treatment with an iron-chelating agent.

Authors:  N Bowern; I A Ramshaw; I A Clark; P C Doherty
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.